Transcoronary Bone Marrow‐Derived Progenitor Cells in a Child With Myocardial Infarction: First Pediatric Experience

Limsuwan, Alisa; Pienvichit, Pavit; Limpijankit, Thosaphol; Khowsathit, Pongsak; Hongeng, Suradej; Pornkul, Ratanaporn; Siripornpitak, Suvipaporn; Boonbaichaiyapruk, Sarana

doi:10.1002/clc.20463

Cited by 21 publications

(13 citation statements)

References 19 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, Limsuwan et al[ 37 ] applied the first daily injections of G-CSF, followed by bone marrow aspiration and selection of CD133 + /CD34 + cells in an 8.5-year-old girl who had had an acute extensive anterior myocardial infarction related to Takayasu arteritis one year earlier. The selected stem cells were injected into the left anterior descending artery with the stop-flow technique.…”

Section: Discussionmentioning

confidence: 99%

Clinical cardiac regenerative studies in children

Pávó

Michel‐Behnke

2017

WJC

View full text Add to dashboard Cite

Although the incidence of pediatric heart failure is low, the mortality is relatively high, with severe clinical symptoms requiring repeated hospitalization or intensive care treatment in the surviving patients. Cardiac biopsy specimens have revealed a higher number of resident human cardiac progenitor cells, with greater proliferation and differentiation capacity, in the neonatal period as compared with adults, demonstrating the regeneration potential of the young heart, with rising interest in cardiac regeneration therapy in critically ill pediatric patients. We review here the available literature data, searching the MEDLINE, Google Scholar and EMBASE database for completed, and www.clinicaltrials.gov homepage for ongoing studies involving pediatric cardiac regeneration reports. Because of difficulties conducting randomized blinded clinical trials in pediatric patients, mostly case reports or cohort studies with a limited number of individuals have been published in the field of pediatric regenerative cardiology. The majority of pediatric autologous cell transplantations into the cardiac tissue have been performed in critically ill children with severe or terminal heart failure. Congenital heart disease, myocarditis, and idiopathic hypertrophic or dilated cardiomyopathy leading to congestive heart failure are some possible areas of interest for pediatric cardiac regeneration therapy. Autologous bone marrow mononuclear cells, progenitor cells, or cardiospheres have been applied either intracoronary or percutaneously intramyocardially in severely ill children, leading to a reported clinical benefit of cell-based cardiac therapies. In conclusion, compassionate use of autologous stem cell administration has led to at least short-term improvement in heart function and clinical stability in the majority of the critically ill pediatric patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical cardiac regenerative studies in children

Pávó

Michel‐Behnke

2017

WJC

View full text Add to dashboard Cite

show abstract

“…The nine-year-old patient received bone marrow CD133+/CD34+ cells using a transcoronary catheter without any complication. Three months after the cell therapy treatment, the LVEF (by cardiac magnetic resonance and echocardiogram) improved from 30% at baseline to 47% [ 47 ].…”

Section: Cell-based Therapy Experience In Patients With Chd or Heamentioning

confidence: 99%

Stem Cell Therapy and Congenital Heart Disease

Nelson

Peral

2016

JCDD

View full text Add to dashboard Cite

For more than a decade, stem cell therapy has been the focus of intensive efforts for the treatment of adult heart disease, and now has promise for treating the pediatric population. On the basis of encouraging results in the adult field, the application of stem cell-based strategies in children with congenital heart disease (CHD) opens a new therapy paradigm. To date, the safety and efficacy of stem cell-based products to promote cardiac repair and recovery in dilated cardiomyopathy and structural heart disease in infants have been primarily demonstrated in scattered clinical case reports, and supported by a few relevant pre-clinical models. Recently the TICAP trial has shown the safety and feasibility of intracoronary infusion of autologous cardiosphere-derived cells in children with hypoplastic left heart syndrome. A focus on preemptive cardiac regeneration in the pediatric setting may offer new insights as to the timing of surgery, location of cell-based delivery, and type of cell-based regeneration that could further inform acquired cardiac disease applications. Here, we review the current knowledge on the field of stem cell therapy and tissue engineering in children with CHD, and discuss the gaps and future perspectives on cell-based strategies to treat patients with CHD.

show abstract

“…after transcoronary infusion of BMC, lvef improved from 30% to 47%. 22 although all studies to date are limited to case reports with small numbers of patients, the dramatic improvements shown in most of these studies lead to the assumption that children have a greater potential of heart regeneration and reactivity to cell therapy. to uncover the efficacy of cell therapy beyond its feasibility and safety, further study is necessary, including largescale randomized clinical trials.…”

Section: Introductionmentioning

confidence: 99%